Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.41 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | IL1RN | P18510 | 1/20 | 0.40 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL569725 | 0.76 | CES1 (0.59) | CES1MAPK1SMN1; SMN2LMNAHPGD | |
| SCHEMBL14310498 | 0.76 | CES1 (0.59) | CES1MAPK1SMN1; SMN2LMNAHPGD | |
| SCHEMBL216185 | 0.75 | PTPN1 (0.62) | MAPK1SMN1; SMN2CA1CA2KEAP1 | |
| SCHEMBL14033372 | 0.75 | LMNA (0.59) | MAPK1SMN1; SMN2LMNAHPGDCA1 | |
| SCHEMBL6877688 | 0.74 | CES1 (0.57) | CES1SMN1; SMN2MAPTNPSR1SRC | |
| SCHEMBL28665290 | 0.74 | PTPN1 (0.60) | MAPK1SMN1; SMN2CA1CA2KEAP1 | |
| SCHEMBL1976973 | 0.74 | PTPN1 (0.60) | MAPK1SMN1; SMN2CA1CA2KEAP1 | |
| SCHEMBL14571964 | 0.73 | CA2 (0.54) | MAPK1SMN1; SMN2CA12CA9CA1 | |
| SCHEMBL822805 | 0.72 | CA12 (0.65) | CES1SMN1; SMN2CA12CA9CA1 | |
| SCHEMBL19042259 | 0.72 | CA2 (0.49) | MAPK1SMN1; SMN2CA1CA2KEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2011524358-A | — | — | 2011-09-01 | — | — | JP | claimed |
| EP-2320893-A1 | COMBINATION OF A TRIPTAN AND AN NSAID | Elan Pharma International Limited (IE) | 2011-05-18 | — | — | EP | claimed |
| US-20090311335-A1 | COMBINATION OF A TRIPTAN AND AN NSAID | ALKERMES, INC. | 2009-12-17 | — | — | US | claimed |
| WO-2009152192-A1 | COMBINATION OF A TRIPTAN AND AN NSAID | ELAN PHARMA INTERNATIONAL LIMITED (IE) | 2009-12-17 | — | — | WO | claimed |
| EP-1617816-B1 | NANOPARTICULATE MELOXICAN FORMULATIONS | ELAN PHARMA INT LTD (IE) | 2009-05-13 | — | — | EP | claimed |
| EP-1938803-A2 | Formulations comprising nanoparticulate meloxican | Elan Pharma International Limited (IE) | 2008-07-02 | — | — | EP | claimed |
| EP-1617816-A2 | NANOPARTICULATE MELOXICAN FORMULATIONS | Elan Pharma International Limited (IE) | 2006-01-25 | — | — | EP | claimed |
| WO-2005002542-A2 | NANOPARTICULATE MELOXICAN FORMULATIONS | ELAN PHARMA INTERNATIONAL LTD. (IE) | 2005-01-13 | — | — | WO | claimed |
| US-20040229038-A1 | Nanoparticulate meloxicam formulations | ELAN PHARMA INTERNATIONAL LTD. | 2004-11-18 | — | — | US | claimed |
| US-11717481-B2 | Reduction of flake-like aggregation in nanoparticulate active agent compositions | ALKERMES PHARMA IRELAND LIMITED (IE) | 2023-08-08 | — | — | US | disclosed |
| US-20220211626-A1 | REDUCTION OF FLAKE-LIKE AGGREGATION IN NANOPARTICULATE ACTIVE AGENT COMPOSITIONS | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2022-07-07 | — | — | US | disclosed |
| US-20210113580-A1 | NANOPARTICULATE MELOXICAM FORMULATIONS | BAUDAX BIO, INC. | 2021-04-22 | — | — | US | disclosed |
| EP-3434261-B1 | FORMULATIONS COMPRISING NANOPARTICULATE MELOXICAM | BAUDAX BIO INC (US) | 2020-10-28 | — | — | EP | disclosed |
| US-10709713-B2 | Nanoparticulate meloxicam formulations | BAUDAX BIO, INC. (US) | 2020-07-14 | — | — | US | disclosed |
| WO-2005016310-A1 | NOVEL METAXALONE COMPOSITIONS | ELAN PHARMA INTERNATIONAL LTD. (IE) | 2005-02-24 | — | — | WO | disclosed |
| WO-2005002542-A2 | NANOPARTICULATE MELOXICAN FORMULATIONS | ELAN PHARMA INTERNATIONAL LTD. (IE) | 2005-01-13 | — | — | WO | disclosed |
| US-20040229038-A1 | Nanoparticulate meloxicam formulations | ELAN PHARMA INTERNATIONAL LTD. | 2004-11-18 | — | — | US | disclosed |
| US-20040173696-A1 | Milling microgram quantities of nanoparticulate candidate compounds | ELAN PHARMA INTERNATIONAL LTD. | 2004-09-09 | — | — | US | disclosed |
| US-20040156872-A1 | Novel nimesulide compositions | ELAN PHARMA INTERNATIONAL LTD. | 2004-08-12 | — | — | US | disclosed |
| WO-2004058216-A2 | MILLING MICROGRAM QUANTITIES OF NANOPARTICULATE CANDIDATE COMPOUNDS | ELAN PHARMA INTERNATIONAL LTD. (IE) | 2004-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040156872-A1 | Novel nimesulide compositions | NIM1K, NIT2, NCL | CES1 4770/4885MAPK1 4591/4885SMN1; SMN2 136/4885 |
| US-10709713-B2 | Nanoparticulate meloxicam formulations | MTNR1A, MB, MTDH | CES1 4747/4885MAPK1 3547/4885SMN1; SMN2 542/4885 |
| US-20210113580-A1 | NANOPARTICULATE MELOXICAM FORMULATIONS | MTNR1A, MB, MTDH | CES1 4747/4885MAPK1 3547/4885SMN1; SMN2 542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.